{"entity":{"id":"tasquinimod-10tasq10","kind":"trial","name":"10TASQ10","aka":["10TASQ10","tasquinimod phase 3"],"tldr":"A drug aimed at the tissue around the tumour delayed progression on scans by two and a half months, and the men who took it lived, if anything, slightly less long.","summary":"10TASQ10 randomly assigned 1,245 men with chemotherapy-naive metastatic castration-resistant prostate cancer and bone metastases 2:1 to tasquinimod (832) or placebo (413). Median age was 71, 77.3 percent had a Karnofsky performance status of 90 percent or more and 21.1 percent had visceral metastases.\n\nEstimated median radiographic progression-free survival by central review was 7.0 months (95 percent confidence interval 5.8 to 8.2) with tasquinimod and 4.4 months (3.5 to 5.5) with placebo, hazard ratio 0.64 (0.54 to 0.75, p<0.001). Median overall survival was 21.3 months (19.5 to 23.0) with tasquinimod and 24.0 months (21.4 to 26.9) with placebo, hazard ratio 1.10 (0.94 to 1.28, p=0.25).\n\nGrade 3 or worse adverse events were more frequent with tasquinimod (42.8 against 33.6 percent), the commonest being anaemia, fatigue and cancer pain.\n\nTasquinimod and orteronel are the pair that should be quoted whenever radiographic progression-free survival is proposed as a registrational endpoint in prostate cancer. Both moved it a long way. Neither moved survival, and one moved it in the wrong direction.","status":"negative","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT01234311","url":"https://clinicaltrials.gov/study/NCT01234311"},{"label":"10TASQ10 (Journal of Clinical Oncology 2016)","url":"https://doi.org/10.1200/JCO.2016.66.9697"}],"tags":[],"related":[],"cancers":["prostate","prostate-mcrpc"],"sections":[],"technologies":["antiangiogenic"],"targets":[],"drugs":["tasquinimod"],"companies":["active-biotech","ipsen"],"institutions":[],"pathways":[],"terms":["castration-resistance","bone-metastases"],"trials":["elm-pc-4-orteronel"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01234311","phase":"3","setting":"Chemotherapy-naive metastatic castration-resistant prostate cancer with bone metastases: tasquinimod once daily against placebo, randomised 2:1, until progression or toxicity, with radiographic progression-free survival as the primary endpoint and overall survival as the key secondary endpoint","sponsor":"Active Biotech with Ipsen","result":"Median radiographic progression-free survival 7.0 against 4.4 months (hazard ratio 0.64, 95 percent confidence interval 0.54 to 0.75, p<0.001) but overall survival 21.3 against 24.0 months (1.10, 0.94 to 1.28, p=0.25).","yearReported":2016,"enrolled":1245,"enrolledBasis":"randomised","enrolledNote":"1,245 men were randomly assigned 2:1 between March 2011 and December 2012 at 241 sites in 37 countries.","outcomes":[{"endpoint":"Radiographic progression-free survival (median)","primary":true,"unit":"months","arms":[{"name":"Tasquinimod","n":832,"value":7},{"name":"Placebo","n":413,"value":4.4}],"hr":0.64,"ci":[0.54,0.75],"p":"<0.001","source":"https://doi.org/10.1200/JCO.2016.66.9697"},{"endpoint":"Overall survival (median)","unit":"months","arms":[{"name":"Tasquinimod","n":832,"value":21.3},{"name":"Placebo","n":413,"value":24}],"hr":1.1,"ci":[0.94,1.28],"p":"0.25","source":"https://doi.org/10.1200/JCO.2016.66.9697"}],"replication":"ELM-PC 4 with orteronel produced the same dissociation in 1,560 men."},"route":"/trials/tasquinimod-10tasq10/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"}],"drug":[{"id":"tasquinimod","kind":"drug","name":"Tasquinimod","route":"/drugs/tasquinimod/"}],"company":[{"id":"active-biotech","kind":"company","name":"Active Biotech","route":"/companies/active-biotech/"},{"id":"ipsen","kind":"company","name":"Ipsen","route":"/companies/ipsen/"}],"term":[{"id":"bone-metastases","kind":"term","name":"Bone metastases and skeletal-related events","route":"/terms/bone-metastases/"},{"id":"castration-resistance","kind":"term","name":"Castration-resistant prostate cancer (CRPC)","route":"/terms/castration-resistance/"},{"id":"prostate-failed-programmes","kind":"term","name":"Prostate cancer programmes that failed, and what each failure taught","route":"/terms/prostate-failed-programmes/"}],"trial":[{"id":"comet-1","kind":"trial","name":"COMET-1","route":"/trials/comet-1/"},{"id":"elm-pc-4-orteronel","kind":"trial","name":"ELM-PC 4","route":"/trials/elm-pc-4-orteronel/"}]}}